Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient

Steven A. Yukl1,3, Eli Boritz2,3, Michael Busch3, Christopher Bentsen4, Tae-Wook Chun5, Daniel Douek2, Evelyn Eisele6, Ashley Haase7, Ya-Chi Ho6, Gero Hütter8, J. Shawn Justement5, Sheila Keating3, Tzong-Hue Lee7, Pellin Li1, Danielle Murray9, Sarah Palmer9, Christopher Pilcher10, Satish Pillai1, Richard W. Price11, Meghan Rothenberger9, Timothy Schacker7, Janet Siliciano6, Robert Siliciano6,12, Elizabeth Sinclair10, Matt Strain13, Joseph Wong1, Douglas Richman13, Steven G. Deeks10

1 San Francisco VA Medical Center (SFVA) and University of California, San Francisco (UCSF), San Francisco, California, United States of America, 2 Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, United States of America, 3 Blood Systems Research Institute (BSRI), San Francisco, California, United States of America, 4 Bio-Rad Laboratories, Redmond, Washington, United States of America, 5 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 6 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 7 University of Minnesota, Minneapolis, Minnesota, United States of America, 8 Institute of Transfusion Medicine and Immunology, Heidelberg University, Mannheim, Germany, 9 Department of Diagnostics and Vaccinology, Swedish Institute for Infectious Disease Control and Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden, 10 Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, United States of America, 11 Department of Neurology, University of California, San Francisco (UCSF), San Francisco, California, United States of America, 12 Howard Hughes Medical Institute, Baltimore, Maryland, United States of America, 13 University of California San Diego (UCSD), La Jolla, California, and Veterans Affairs San Diego Healthcare System, San Diego, California, United States of America

Abstract

There is intense interest in developing curative interventions for HIV. How such a cure will be quantified and defined is not known. We applied a series of measurements of HIV persistence to the study of an HIV-infected adult who has exhibited evidence of cure after allogeneic hematopoietic stem cell transplant from a homozygous CCR5Δ32 donor. Samples from blood, spinal fluid, lymph node, and gut were analyzed in multiple laboratories using different approaches. No HIV DNA or RNA was detected in peripheral blood mononuclear cells (PBMC), spinal fluid, lymph node, or terminal ileum, and no replication-competent virus could be cultured from PBMCs. However, HIV RNA was detected in plasma (2 laboratories) and HIV DNA was detected in the rectum (1 laboratory) at levels considerably lower than those expected in ART-suppressed patients. It was not possible to obtain sequence data from plasma or gut, while an X4 sequence from PBMC did not match the pre-transplant sequence. HIV antibody levels were readily detectable but declined over time; T cell responses were largely absent. The occasional, low-level PCR signals raise the possibility that some HIV nucleic acid might persist, although they could also be false positives. Since HIV levels in well-treated individuals are near the limits of detection of current assays, more sensitive assays need to be developed and validated. The absence of recrudescence HIV replication and waning HIV-specific immune responses five years after withdrawal of treatment provide proof of a clinical cure.

Citation: Yukl SA, Boritz E, Busch M, Bentsen C, Chun T-W, et al. (2013) Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient. PLoS Pathog 9(5): e1003347. doi:10.1371/journal.ppat.1003347

Editor: Bryan R. Cullen, Duke University Medical Center, United States of America

Received November 6, 2012; Accepted March 20, 2013; Published May 9, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This work was primarily supported by the Foundation for AIDS Research (amFAR). Additional support was provided by the Delaney AIDS Research Enterprise (DARE, U19AI0961090), the Department of Veterans Affairs (1IK2CX000520-01), the Intramural Research Program of the NIAID, the NIH Office of AIDS Research, the Collaboratory for AIDS Research on Eradication (CARE) from the National Institutes of Health (awards AI 080193, A1069432, AI077475, AI74621, AI305214 [CFAR], and AI096613), and the James Pendleton Charitable Trust. UCSF Options study work was supported by NIAID (P01 AI071713) and the Consortium for the Performance of HIV Incidence Assays (CEPHIA), with funding from the Bill and Melinda Gates Foundation. The UCSF SCOPE cohort was also supported by NIAID (R01 AI087145, K24 AI069994), the UCSF/Gladestone Institute of Virology & Immunology CFAR (P30 AI027763), and the UCSF Clinical and Translational Research Institute Clinical Research Center (UL1 RR024131). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: Michael Busch has consulted for Gen-Probe (now owned by Hologic), which provided support for some of the virologic measurements performed in this study. Christopher Bentsen is currently employed by Bio-Rad Laboratories, Inc. and received salary, benefits and stock. He oversaw the testing of samples in this paper with FDA approved tests from Bio-Rad. These relationships do not alter our adherence to all PLoS Pathogens policies on sharing data and materials.

* E-mail: sdeeks@php.ucsf.edu

† These authors contributed equally to this work.

Introduction

Given the well-recognized limitations of antiretroviral therapy (ART)—which include side effects, costs, and difficulties delivering complex regimens to a global population for decades—there is intense interest in curative interventions [1,2]. This interest in curative strategies is also driven by a single case report in which a cure was apparently achieved [3]. In 2007, an HIV-infected adult
Author Summary

There is intense interest in developing a cure for HIV. How such a cure will be quantified and defined is not known. We applied a series of measurements of HIV persistence to the study of an HIV+ adult who has exhibited evidence of cure after a stem cell transplant. Samples from blood, spinal fluid, lymph node, and gut were analyzed in multiple laboratories using different approaches. No HIV was detected in blood cells, spinal fluid, lymph node, or small intestine, and no infectious virus was recovered from blood. However, HIV was detected in plasma (2 laboratories) and HIV DNA was detected in the rectum (1 laboratory) at levels considerably lower than those expected in antiretroviral treated patients. The occasional, low-level HIV signals might be due to persistent HIV or might reflect false positives. The sensitivity of the current generation of assays to detect HIV RNA, HIV DNA, and infectious virus are close to the limits of detection. Improvements in these tests will be needed for future curative studies. The lack of rebounding virus after five years without therapy, the failure to isolate infectious virus, and the waning HIV-specific immune responses all indicate that the Berlin Patient has been effectively cured.

living in Berlin developed acute myelogenous leukemia (AML), for which he was treated with an allogeneic hematopoietic stem cell transplant from a donor who was homozygous for the CCR5Δ32 deletion [3], which confers resistance to infection with CCR5-utilizing virus. The patient interrupted ART soon after the transplant and has had no detectable plasma HIV RNA for over five years [3,4]. Previous studies reported that: 1) he lacked HIV RNA in cerebrospinal fluid (CSF) [4]; 2) he had no detectable HIV DNA in PBMC, bone marrow, brain, or colon [3,4]; 3) HIV-specific T cell responses decreased after the transplant [3]; and 4) he lost antibodies to Pol and Gag but not Env [3]. Although CCR5-expressing cells were detected in the colon at 5.5 months post-transplant [3], no CCR5-expressing cells were detected in the colon at later time points or in the liver or the brain [4].

Despite the unquestioned success of the transplant, theoretical reasons suggest that HIV could survive the transplant. These include: 1) the possible presence of X4-tropic virus prior to transplant [3,5]; 2) the detection of rare CCR5+ macrophages 5.5 months after transplant [3]; and 3) the possibility of long lived nonhematopoietic cell reservoirs [6] that could produce virus even if the ability to replicate were constrained by lack of CCR5-expressing hematopoietic cells.

In most ART-suppressed patients, the level of persistent HIV is very low. Even with single copy assays, some patients have essentially no detectable HIV RNA in plasma (i.e., <0.1–1 copy/mL, depending on volume) [7], and only one in approximately a million circulating CD4+ T cells contains replication-competent virus [8,9,10,11,12]. The burden of HIV may be higher in the lymphoid tissues [8,13,14,15] and gut [16,17,18]. As most long-term treated adults have HIV burdens that are near or at the sensitivity of current assays, it is unclear as to whether such assays will be amenable to monitoring virologic responses to future curative interventions.

In 2011, the Berlin Patient transferred his care to San Francisco and consented to a series of studies aimed at determining if HIV persisted. Multiple samples were obtained from a number of different sites, including lymphoid tissues, and relatively large biological inputs were analyzed using the most sensitive assays available. Our objectives were to determine whether the transplant resulted in a sterilizing cure and to assess the capacity of currently available assays to detect and quantify possible low-level persistence.

Methods

The subject was enrolled in the UCSF-based SCOPE cohort and had multiple study visits over two years (Figure 1). Plasma, serum, and PBMC were obtained at each visit. The subject also consented to separate procedures at UCSF, including leukapheresis, lumbar puncture, and sigmoidoscopy with rectal biopsies. He was also seen at the University of Minnesota, where he underwent a lymph node biopsy and a colonoscopy with ileal and rectal biopsies. In order to compare HIV antibody levels in the subject with those from HIV-infected and HIV-uninfected subjects, blood samples were analyzed from participants in another UCSF based pathogenesis cohort, the Options study. All procedures were approved by the Institutional Review Boards at UCSF and the University of Minnesota.

Samples and labs

Samples (plasma, PBMC, CSF, lymph node, gut biopsies) were analyzed in a number of different laboratories with expertise in detecting extremely low levels of virus, including the Blood Systems Research Institute (BSRI); Johns Hopkins; the National Institutes of Health (NIH); the Karolinska Institutet in Solna, Sweden; the University of California San Diego (UCSD); the University of California, San Francisco (UCSF); and the University of Minnesota.

Plasma and PBMC

Plasma HIV RNA was measured in 4 different laboratories using 4 different techniques: 1) Roche Ampliprep assay [19]; 2) single copy assay [7,20] (SCA); 3) Transcription-Mediated Amplification (TMA) [21,22]; and 4) a modified Abbott assay that involves pelleting virus from 30 ml of plasma [23] (Table 1). Cell-associated HIV DNA in PBMC was measured in 4 laboratories using qPCR [19,22,24,25] or digital droplet PCR [26] (Table 2). Cell-associated HIV RNA in PBMC was measured in 3 laboratories using the Roche Ampliprep [19], qRT-PCR [24] or TMA [22]. Latently-infected peripheral CD4+ T cells (in infectious units per million cells, IUPM) were measured in 2 laboratories by co-culture [27,28].

CSF

Lumbar puncture was performed once (Table 3). The CSF was spun down to yield 8,400 cells, which were tested for HIV DNA in one laboratory [19]. The supernatant CSF was tested for HIV RNA in two laboratories [7,19].

Sigmoidoscopy

Thirty rectal biopsies were obtained by sigmoidoscopy. Six biopsies were snap frozen, while 24 biopsies were digested with collagenase [18] to yield total rectal cells, which were counted, aliquoted, and frozen. Total DNA and RNA were isolated from each aliquot of rectal biopsies and rectal cells using TriReagent (Molecular Research Center). RNA was further treated with RNase-free DNase (Qiagen) and purified using Qiagen RNEasy kits. DNA and RNA from each aliquot of rectal biopsies and rectal cells were tested for HIV in one laboratory using qPCR and qRT-PCR for the LTR [24] and normalized to cell equivalents by DNA or RNA mass, as determined by Nanodrop.
Colonoscopy and Lymph Node (LN) biopsy

Colonoscopy and inguinal LN biopsy were performed at Minnesota. Tissue sections from LN, ileum, and rectum were assessed for HIV RNA by in situ hybridization [ISH] [13]. Sections were taken at 20 μ intervals, and two individuals examined each section. The portion of LN that was not placed in fixative was immediately suspended in liquid nitrogen, while the remaining gut biopsies were digested with collagenase to obtain total gut cells. LN tissue and cryopreserved cells from blood and gut were then sent to the NIH, where subsequent procedures included cell sorting (blood and gut), whole transcriptome sequencing, and fluorescence-assisted clonal amplification of HIV env.

Cell sorting

PBMC and gut cell suspensions were stained with LIVE/DEAD violet stain (Molecular Probes) and the following fluorescently-conjugated antibodies: CCR5-Cy7PE (Pharmingen); CD45RO-PE-Texas Red (Coulter); CD14-PE (Pharmingen); CD11c-PE (Pharmingen); CD3-H7APC (BD); T cell receptor-δ-APC (Pharmingen); CD20-APC (BD); CD56-APC (Pharmingen); CD45-Qdot 800 (Invitrogen); CD8-Qdot 655 (Invitrogen); and CD4-Qdot 605 (Invitrogen). Cells were sorted on a FACS Aria into four subsets for each tissue, as shown in Figure 2. Viable single cells from PBMC from two time points were sorted into CCR5 + cells, CCR5- non-T cells, CCR5- T cells that were not CD4 +, and CCR5- CD4+ T cells. All gut cells from each site were sorted into one of 4 different populations: non-hematopoietic cells (CD45−); hematopoietic cells (CD45+) that were not T cells; T cells that were not CD4+; and CD4+ T cells.

Fluorescence-assisted clonal amplification (FCA) of HIV envelope

Snap-frozen lymph node tissue and sorted cells were homogenized in RNeasy kit (Molecular Research Center, Inc.), and DNA and total RNA were extracted separately. DNA samples were diluted to a concentration of ≤5,000 cell equivalents per well in 384-well plates and amplified with HIV env-specific primers ESf2 (CCGGCTGGTTTTGCGATTCTAAARTG) and ESr1-b (AGGAGCTGTTGATCCTTTAGGTATCTTTC) in PCR reactions containing SYBR Green (Invitrogen). CD4+ T cell genomic DNA from a viremic HIV+ subject was amplified as a positive control. HIV env amplification was detected by SYBR Green fluorescence and specificity was confirmed by melt curve analysis.

Whole transcriptome sequencing

mRNA was purified from the sorted samples above as well as PBMC from two HIV- donors, CD4+T cells from one viremic HIV+ control, and stably-infected ACH-2 cells. Messenger RNA was fragmented, and barcoded libraries were constructed and clustered on an Illumina TrueSeq Paired-End Flowcell v3. The flow cell was sequenced on an Illumina HiSeq 2000 in a 150bp single-read indexed run. Reads were aligned to the human genome (hg19, NCBI Build 37) and transcriptome using TopHat. Unaligned reads were then aligned to the patient’s pre-transplant HIV sequences using Novoalign. Reads that did not align to these sequences were then aligned against all molecular HIV clones on the Los Alamos National Laboratories HIV database. In addition, all unfiltered reads were independently aligned to the patient’s pre-
transplant sequences, the HIV HXB.2 reference sequence, and all molecular HIV clones on the Los Alamos HIV database. Lastly, unfiltered reads were aligned to a wild-type (NM_001100168) and Δ32 CCR5 sequence.

Immune responses to HIV and other infections

Western blot for HIV was performed on blood from one time point (ARUP labs). Blood from four other time points was analyzed for HIV-specific antibody (Ab) at the BSRI using the HIV-1/2 VITROS assay (Ortho Clinical Diagnostics, Rochester, NY), a detuned version of the HIV-1 VITROS assay [29], and the Limiting Antigen Avidity assay (Sedia, Portland, OR) [30]. To assess how these antibody levels compared with levels in typical HIV infection, we compared the detuned VITROS Ab results with those for participants in the UCSF Options study, whose samples were also tested at BSRI. Results were included from subjects who were HIV- uninfected (negative for HIV antibody and HIV RNA); from subjects who were HIV infected for at least one year and ART-naïve; and from subjects who were HIV infected on suppressive ART for at least 6 months.

Antibodies to other infectious diseases, including CMV, EBV, HSV, VZV, hepatitis B, measles, mumps, rubella, and toxoplasmosis, were measured in post-transplant samples from 5/2011 to 2/2012 using Bio-Rad Bioplex 2200 multiplex and MONOLISA microtiter clinical assays. T-cell responses to HIV and CMV were measured once by flow cytometry for intracellular cytokine staining [31].

Results

Plasma HIV RNA

Plasma HIV RNA levels were quantified using several methods. HIV RNA was detected in 2 of 4 laboratories in plasma samples from 3 different time points (Table 1). In one laboratory, HIV RNA was detected by the Roche Ampliprep in 3 of 10 1.0 ml replicates from one time point (each with 1–2 copies, for an average of 0.4 copy/ml), 1 of 24 replicates from a second time point (at 70 copies, for an average of 2.9 copy/ml), and zero of 24 replicates from a third time point. In a separate laboratory, plasma from a fourth time point (17 ml) was positive in 2 of 6 replicates, each with 4–5 copies, for an average of 1 copy/ml. At this level of amplification, false positive signals at the level of 1–2 copies/ml can occasionally be seen, although these controls were negative when this assay was run. No HIV RNA was detected in 2 other laboratories using samples from other independent time points.

HIV DNA and RNA in PBMC

Unfractionated PBMC samples, each from a different time point, were studied in 4 laboratories using HIV sequence-specific PCR or TMA. No HIV DNA or RNA was detected (Table 2). In a fifth laboratory, PBMC samples from two different time points were sorted into CCR5−CD3− (non-T) cells, CCR5+CD4+ T cells, all other CCR5−T cells and, using an inclusive gating strategy to collect all possible events, a cell population that appeared to be CCR5+ by staining (Figure 2a–g). Messenger RNA from each of these sorted populations was negative for HIV by whole transcriptome sequencing, which has been found to yield several hundred HIV-derived reads per sample in comparable experiments on sorted CD4+ T cells from ART-naïve subjects (E. Boritz and D. Douek, unpublished observations). DNA from each of these populations was negative for HIV by fluorescence-assisted clonal amplification of mcs, which detects individual HIV DNA genomes with a sensitivity equivalent to the widely-used quanti-
### Table 2. HIV in blood cells.

| Sample                  | Date       | Lab              | Measure | Input         | Assay                          | Detection Limit | False Positive Rate\(^1\) | Result |
|-------------------------|------------|------------------|---------|---------------|--------------------------------|-----------------|-----------------------------|--------|
| PBMC                    | 5/31/11    | NIH              | HIV DNA | 30 × 10^6 cells | qPCR for LTR [19]               | 0.5–2.6 copy/μg | 0/72 (<1.4%)               | ND\(^2\) |
| PBMC                    | 7/5/11     | SPVA/UCSF        | HIV DNA | 10^6 cells     | qPCR for LTR [24,56]            | 1–2 copy/reaction [56] | 1/130 (0.8%)                | 1 of 10 wells equivocal |
| PBMC                    | 11/17/11   | Johns Hopkins    | HIV DNA | 10^6 cells     | qPCR for Gag [25]               | 1 copy/reaction  | ND                          | $<1$ in 10^6 |
| PBMC                    | 8/1/11     | UCSD             | HIV DNA | 10^6 cells     | Digital droplet PCR for Pol [26] | 0.52 copy/10^6 cells | 7/29 (24%)                 | ND                          |
| PBMC (sorted)           | 2/29/12    | Vaccine Research Center | HIV DNA | 6.7 × 10^6 CCR5^- cells | Fluorescence-assisted clonal amplification of Env | 1 copy/reaction | ND                          |        |
|                         |            |                  |         |               |                                |                 | 7.6 × 10^6 CCR5^- non-T cells | ND                 |
|                         |            |                  |         |               |                                |                 | 3.5 × 10^6 CCR5^- CD4^+ T cells | ND                 |
|                         |            |                  |         |               |                                |                 | 2.1 × 10^6 other CCR5^- T cells | ND                 |
| PBMC                    | 5/31/11    | NIH              | HIV RNA | 10 × 10^6 cells | Roche Amplicom [19]             | 1–2 copy/ml     | 1/179 (0.6%)               | ND $<1$ in 10^7 |
| PBMC                    | 7/5/11     | SPVA/UCSF        | HIV RNA | 10^6 cells     | qRT-PCR for LTR [24,56]        | 1–2 copy/reaction [56] | 0/83 (<1.2%)               | ND $<1$ in 10^6 |
| PBMC                    | 6/20/11    | BSRI             | HIV RNA | 3 × 10^6 cells | TMA [22]                       | 1 copy/ml [22]  | 6/3515 (0.2%)              | ND $<1$ in 3 × 10^6 |
| PBMC (sorted)           | 2/29/12    | Vaccine Research Center | HIV RNA | 6.8 × 10^6 CCR5^- cells | RNA sequencing | 1 read/sample | ND                          |
|                         |            |                  |         |               |                                |                 | 8.6 × 10^6 CCR5^- non-T cells | ND                 |
|                         |            |                  |         |               |                                |                 | 3.4 × 10^6 CCR5^- CD4^+ T cells | ND                 |
|                         |            |                  |         |               |                                |                 | 4.2 × 10^6 other CCR5^- T cells | ND                 |
| Peripheral CD4^+ T cells | 5/31/11    | NIH              | Replication competent HIV (IUPM) | 1.4 × 10^6 cells | Co-culture [27]              |                 | ND                          | $<1$ IU/10^6 cells |
| Resting peripheral CD4^+ T cells | 11/17/11 | Johns Hopkins   | Replication competent HIV (IUPM) | 33 × 10^6 cells | Co-culture [28]             |                 | ND                          | $<1$ IU/10^7 cells |

\(^1\)Historical, as determined from the number of positive wells out of all wells containing samples from HIV- subjects/donors that had been processed and run along with positive samples.

\(^2\)ND = not detected.
Table 3. HIV in tissues.

| Sample                  | Date       | Lab                        | Measure | Input               | Assay                               | Detection Limit | False Positive Rate | Result |
|-------------------------|------------|----------------------------|---------|---------------------|-------------------------------------|-----------------|---------------------|--------|
| CSF cells               | 10/3/11    | NIH                        | HIV DNA | 8,400 cells         | qPCR [19] for LTR                   | 0.5–2.6 copy/μg | 0/72 (<1.4%)        | ND     |
| CSF                     | 10/3/11    | Sweden                     | HIV RNA | 7 ml                | SCA [7]                             | 0.3 copy/ml     | ND                  | ND     |
| CSF                     | 10/3/11    | NIH                        | HIV RNA | 10 ml               | Roche Ampiprep [19]                 | 1–2 copy/ml     | ND                  | ND     |
| Lymph Node              | 3/27/12    | Vaccine Research Center    | HIV DNA | No cell counts available | Fluorescence-assisted clonal amplification of Env | 1 copy/reaction | ND                  | ND     |
| Lymph Node              | 3/27/12    | Vaccine Research Center    | HIV RNA | No cell counts available | RNA sequencing                     | 1 read/sample   | ND                  | ND     |
| Rectal biopsy           | 6/20/11    | SFVA/UCSF                  | HIV DNA | DNA from 2.7×10^6 cells from 3×2 biopsies | qPCR for LTR [24,56] | 1–2 copy/reaction [56] | 1/130 (0.8%) | 2 of 15 wells positive in 10^6 cells |
| Rectal cells (collagenase digestion) | 6/20/11 | SFVA/UCSF                  | HIV DNA | DNA from 1.5×10^6 cells (out of 2×2.4×10^6) | qPCR for LTR [24,56] | 1–2 copy/reaction [56] | 1/130 (0.8%) | 1 of 10 wells positive in 10^6 cells |
| 4 sorted cell populations from rectum | 3/27/12 | Vaccine Research Center | HIV DNA | 3.1×10^5 CD45^− cells | Fluorescence-enabled clonal amplification of Env | 1 copy/reaction | ND                  | ND     |
|                         |            |                            |         | 3.1×10^4 CD45^− non-T cells | ND | ND | ND |
|                         |            |                            |         | 1.3×10^4 CD4^+ T cells | ND | ND | ND |
|                         |            |                            |         | 3.8×10^4 other T cells | ND | ND | ND |
| 4 sorted cell populations from rectum | 3/27/12 | Vaccine Research Center | HIV RNA | 8.5×10^5 CD45^− cells | RNA sequencing | 1 read/sample | ND | ND |
|                         |            |                            |         | 3.2×10^4 CD45^− non-T cells | ND | ND | ND |
|                         |            |                            |         | 1.3×10^4 CD4^+ T cells | ND | ND | ND |
|                         |            |                            |         | 3.8×10^4 other T cells | ND | ND | ND |
| Rectal biopsy           | 6/20/11    | SFVA/UCSF                  | HIV RNA | RNA from 7.8×10^6 cells (from 3×2 biopsies) | qRT-PCR for LTR [24,56] | 1–2 copy/reaction [56] | 0/83 (<1.2%) | ND (≤1 in 7.8×10^6 cells) |
| Rectal cells (collagenase digestion) | 6/20/11 | SFVA/UCSF                  | HIV RNA | RNA from 2.5×10^6 cells (out of 2×2.4×10^6) | qRT-PCR for LTR [24,56] | 1–2 copy/reaction [56] | 0/83 (<1.2%) | ND (≤1 in 2.5×10^6 cells) |
| Rectal Biopsy           | 3/27/12    | Univ. of Minnesota         | HIV RNA | ISH [13]            | 10^3–5 cells/g                      | Rare signal, 7 artifact | ND (≤1 in 10^6 cells) | ND |
| 4 sorted cell populations from ileum | 3/27/12 | Vaccine Research Center | HIV DNA | 8.6×10^5 CD45^− cells | Fluorescence-enabled clonal amplification of Env | 1 copy/reaction | ND (≤1 in 10^6 cells) | ND |
|                         |            |                            |         | 4.9×10^4 CD45^− non-T cells | ND | ND | ND |
|                         |            |                            |         | 2.9×10^4 CD4^+ T cells | ND | ND | ND |
|                         |            |                            |         | 1.0×10^5 other T cells | ND | ND | ND |
| 4 sorted cell populations from ileum | 3/27/12 | Vaccine Research Center | HIV RNA | 8.8×10^5 CD45^− cells | RNA sequencing | 1 read/sample | ND | ND |
|                         |            |                            |         | 5.0×10^4 CD45^− non-T cells | ND | ND | ND |
|                         |            |                            |         | 3.0×10^4 CD4^+ T cells | ND | ND | ND |
|                         |            |                            |         | 1.1×10^5 other T cells | ND | ND | ND |
| Ileal Biopsy            | 3/27/12    | Univ. of Minnesota         | HIV RNA | ISH [13]            | 10^3–5 cells/g                      | ND | ND | ND |

1 Historical, as determined from the number of positive wells out of all wells containing samples from HIV- subjects/donors that had been processed and run along with positive samples.

2 ND = not detected.

doi:10.1371/journal.ppat.1003347.t003
tative PCR assay for HIV gag (E. Boritz and D. Douek, unpublished observations).

Latent HIV in peripheral CD4+T Cells

Co-cultures were performed in two laboratories using peripheral CD4+T cells from leukapheresis and from venous phlebotomy at a second time point. No replication-competent virus was detected (Table 2).

HIV in CSF

Lumbar puncture was performed once. No HIV was detected in the CSF supernatant (2 labs) or cells (1 lab) (Table 3).

HIV in lymph node

One inguinal lymph node was studied in two laboratories (Table 3). No HIV RNA was detected by in situ hybridization or by whole transcriptome sequencing. DNA was negative for HIV by fluorescence-assisted clonal amplification of env.

HIV DNA and RNA in the gut

Whole rectal biopsies and total rectal cells from sigmoidoscopic biopsies were tested for HIV DNA and RNA (Table 3). HIV DNA was detected in DNA isolated from both intact biopsies (2 of 15 wells positive, at 1 and 3 copies) and total rectal cells (1 of 10 wells positive at 1 copy) but not negative controls,
while HIV RNA was not detected in either the rectal cells or rectal biopsies.

Biopsies from the ileum and rectum were obtained by colonoscopy at a second time point and analyzed in 2 other laboratories. No HIV RNA was detected in ileal or rectal tissue by ISH or by whole transcriptome sequencing of mRNA from sorted populations of CD45− (non-hematopoietic) cells, CD45+CD3− (non-T) cells, CD4+T cells, or other T cells from ileum and rectum. DNA from each of these populations was negative for HIV by fluorescence-assisted clonal amplification of env.

Sequence data

No sequence data are available from the samples where HIV was detected in the quantitative assays (plasma and rectum). Cloning and sequencing was not attempted from plasma, as no plasma remained from the three time points that were positive for HIV RNA. Likewise, very little rectal DNA remained after repetitive testing by qPCR, and limited attempts to amplify the env proved unsuccessful.

Figure 3. HIV-specific antibodies. Blood from four time points was tested for HIV specific antibody levels using the HIV-1/2 VITROS assay (3A), a detuned version of the HIV-1 VITROS assay (3B), and the Limiting Antigen avidity assay (3C). The y-axis shows the relative level of total HIV-specific antibody, as expressed as the signal to cutoff ratio (3A–B) or normalized optical density, ODn (3C). The x-axis represents months since transplant. In Figure 3A, the dotted line represents the diagnostic HIV antibody assay cut-off level used to classify individuals as HIV-positive or HIV-negative. For purposes of comparison, HIV antibody responses were also measured in HIV-uninfected adults, untreated HIV-infected adults, and ART-treated chronically-infected adults using the detuned HIV-1 VITROS assay (Figure 3D). The bars in the scatterplots represent the median and interquartile ranges of distributions of seroreactivity for each group. Finally, samples from the Berlin Patient were tested for antibodies to other infectious diseases (3E). Tests included antibodies to CMV (strong positive, above the limit of detection), EBV, measles, and hepatitis B (all within the range of detection) as well as VZV, mumps, rubella, and toxoplasmosis (all negative, below the limit of detection). Only the results within detectable range of the assay are shown. S/CO = signal/cutoff ratio; ODn = normalized optical density; AI = antibody index.

Although no HIV was detected in the PBMC by quantitative assays, two labs attempted to amplify and clone env from PBMC. Sequencing from one laboratory revealed a subtype B HIV-1 envelope (predicted to be X4) that does not match any known sequence but is also highly divergent from the pre-transplant consensus R5 sequence (16.5% genetic distance). Sequences obtained from PBMC in a second laboratory were consistent with a lab contaminant.

CCR5 expression

Whole transcriptome sequencing reads from lymph node and sorted subsets of PBMC, ileal cells, and rectal cells were aligned against the CCR5 reference. All 548 reads aligning to the area of the CCR5Δ32 deletion were consistent with the Δ32 sequence of CCR5. Of particular interest were the CCR5 sequences transcribed by the PBMC populations that appeared to express CCR5 protein by flow cytometry. Though these populations were quite sparse (for example, see Figure 2d), they were sorted separately to ensure directed molecular analysis of any potential
Figure 4. HIV Gag-specific cell mediated immune responses. PBMC were obtained from the Berlin Patient (solid red circles), HIV-uninfected adults (open black circles in 4A–B), chronically HIV-infected adults on long term ART with undetectable plasma viral loads (open black circles, 4C–D), and elite controllers (open black circles, 4E–F). PBMC were stimulated with CMV pp65 or HIV Gag peptide pools, and flow cytometry was used to
measure the percentage of CD4+T cells (4A, 4C, 4E) or CD8+T cells (4B, 4D, 4F) with intracellular staining for interferon-γ, tumor necrosis factor-α, IL-2, or CD107. The y axis shows the percent of T cells that express each cytokine in response to HIV Gag. The solid red circle indicates the Berlin Patient, while open black circles indicate individuals from comparator groups.

doi:10.1371/journal.ppat.1003347.g004

HIV-specific antibody (Ab)

Western blot was 2+ (strongly positive) for gp160, + or − for p24, and negative for other bands (inconclusive, possibly infected). Blood from four other time points was analyzed using 3 different serological assays. Using the undiluted HIV-1/2 VITROS assay, HIV Ab was readily detectable and relatively stable at all 4 time points, with levels considerably above the cutoff for HIV negative individuals (Figure 3A) but beyond the dynamic range of the assay. In the detuned HIV-1 VITROS assay, HIV specific Ab were detectable at levels that were above those seen in HIV-negative individuals but below those seen in HIV-infected individuals before and after long term suppressive ART (Figure 3D). Moreover, HIV Ab levels tended to decrease over time by both the detuned VITROS and the Limiting Antigen Avidity assays (Figure 3B-C). We screened post-transplant samples for chronic infections using several multiplex commercial assays and identified three viruses (EBV, hepatitis B, and measles) against which the subject had serologic responses that were positive but not above the dynamic range of the assays. In contrast with HIV Ab levels, Ab levels for these viruses remained stable over a 9 month period post-transplant (Figure 3E).

HIV-specific T cell responses

PBMC were stimulated with CMV pp65 or HIV Gag peptide pools, and flow cytometry was used to measure the frequencies of CD1+ and CD8+T cells with intracellular staining for cytokines. HIV Gag-specific responses from the subject were compared to responses in at-risk HIV-uninfected adults, chronically HIV-infected adults on long term ART with undetectable plasma HIV RNA levels, and chronically infected adults controlling HIV in the absence of therapy (“elite” controllers). The frequencies of T cells expressing or producing CD107, interferon-γ, IL-2 and TNF-α were generally consistent with the levels seen in HIV-uninfected adults (Figures 4A-B), lower than those observed in HIV-infected adults on long-term combination antiretroviral therapy (Figures 4C-D), and much lower than those observed in elite controllers (Figures 4E-F). In contrast, CMV-specific responses were robust and higher than those observed in HIV-uninfected adults (data not shown) [30].

Discussion

Multiple measurements of HIV persistence were applied to the study of the “Berlin Patient,” who has achieved an apparent cure after a hematopoietic stem cell transplant from a homozygous CCR5Δ32 donor. The vast majority of assays revealed no evidence for persistent HIV, confirming prior reports [3,4], although 3 independent laboratories detected low level PCR signals in 4 different samples from 2 sites (plasma and rectum). The calculated HIV levels were much lower than typical ART-treated patient patients (Table 4) and close to the detection limit of the

Table 4. Summary of virologic measures.

| Sample           | Measure      | # Labs tested samples | # Labs with + Test | Consensus                  | Typical levels in ART-suppressed patient | Fold Difference |
|------------------|--------------|-----------------------|--------------------|----------------------------|-----------------------------------------|-----------------|
| Plasma           | HIV RNA      | 4                     | 2 labs (3 samples) | ?intermittent positive, <1 copy/ml | 1–2 copy/ml                             | 2–20            |
| PBMC             | HIV DNA      | 4                     | 0                  | Negative (≤1 in 10^5–7)       | 751 per 10^10 total PBMC [18]           | 750–7500        |
| PBMC             | HIV RNA      | 3                     | 0                  | Negative (≤1 in 10^5–7)       | 66 per 10^10 total PBMC [18]            | 66–660          |
| Sorted cells from blood | HIV RNA      | 1                     | 0                  | Negative                     | Unknown                                  |                 |
| Sorted cells from blood | HIV RNA      | 1                     | 0                  | Negative                     | Unknown                                  |                 |
| Peripheral CD4+T | IUPM         | 2                     | 0                  | Negative (≤1 IU/10^6 cells)   | 1 per 10^4 CD4+T [8,9,11,12]            | 10–1000         |
| CSF              | HIV RNA      | 2                     | 0                  | Negative                     | Unknown                                  |                 |
| CSF cells        | HIV DNA      | 1                     | 0                  | Negative                     | ≤4 log10 copies/g (FDC) [14]            |                 |
| Lymph node       | HIV RNA      | 1                     | 0                  | Negative                     | 1–12 copies/100 ng [14]                 |                 |
| Lymph Node       | HIV RNA      | 1                     | 0                  | Negative                     | ≤4 log10 copies/g (FDC) [14]            |                 |
| Rectum (biopsy or cells) | HIV DNA      | 2                     | 1                  | ?intermittent positive, <1 in 10^5 cells | 777 per 10^5 total gut cells [18] | 780             |
| Rectum (biopsy or cells) | HIV RNA      | 3                     | 0                  | Negative (<1 in 10^5–7)       | 21 per 10^5 total gut cells [18]        | 21–210          |
| Ileum (biopsy or cells) | HIV DNA      | 1                     | 0                  | Negative (≤1 in 10^5)        | 415 per 10^5 total gut cells [18]      | 415             |
| Ileum (biopsy or cells) | HIV RNA      | 2                     | 0                  | Negative (≤1 in 10^5)        | 37 per 10^5 total gut cells [18]        | 37              |

doi:10.1371/journal.ppat.1003347.t004
most sensitive assays. Replication-competent virus was not detected in PBMC, and HIV-specific antibody (as measured by detuned assays) tended to decline over the 18 months of observation. HIV-specific T cell responses were not detected.

The positive signals can be interpreted in two ways. The first possibility is that all 4 signals could be false positives, perhaps due to nonspecific amplification (e.g., from human endogenous retroviruses) or from contamination of from other clinical samples or lab viruses. The relatively large inputs of biological material and large numbers of replicates may have afforded more opportunities for nonspecific amplification or contamination, especially at copy numbers that are close to the limits of assay detection. Negative controls were run alongside the patient samples for all but the automated Roche assay, and they remained uniformly negative. However, the number of negative controls was generally less than the number of patient wells. For future studies, it may be better to have blinded samples in which the tests are mixed with an equal or greater number of negative controls.

To better approximate the rate of false positives in a larger number of samples, we used data from other experiments to determine the number of positives among all wells containing samples from HIV-uninfected donors that had been extracted and run along with positive samples. Depending on the number of samples tested, false positives could be documented for most assays (Tables 1–5). In one assay for plasma HIV RNA, the false positive rate of 22% was not much lower than the fraction of positive wells observed for the Berlin Patient (33%), increasing the probability that these may have been false positives. For other assays, the false positive rate was considerably lower than the fraction of positive wells observed for the Berlin Patient, although it is also possible that false positives reactions could occur above the “predetermined” rate.

The second possibility is that one or more of these signals were true positives. If HIV persists at extremely low levels or in nonhomogeneous foci, the detection could be inconsistent and could depend on sampling variability, sample volume, number of replicates, or differences in sensitivities of the various assays. In addition, some assays did not rigorously control for inhibitors of PCR, which can contribute to false negatives. However, even if some HIV DNA or RNA sequence persists, the significance of this finding is uncertain, as most proviral DNA is transcriptionally silent [18,32] and/or defective [33,34], and most HIV virions are silent [18,32] and/or defective [33,34], and most HIV virions are not infectious [35]. One recent study suggests that the number of resting CD4+ T cells with defective proviruses may be an average of 300 fold higher than the number that can produce replication-competent virus following cellular activation [36].

Despite the PCR signals from plasma, no replication-competent virus could be cultured from circulating blood cells. The vast majority of ART-treated subjects have detectable replication-competent virus using current co-culture assays, particularly if large number of cells are studied, as was the case in this study. Virus isolation is often more challenging in “elite” controllers, however, suggesting these assays have limited sensitivity to detect rare events. Also, it is worth noting that co-cultures would have had large number of cells studied, as was the case in this study. Virus isolation is often more challenging in “elite” controllers, suggesting these assays have limited sensitivity to detect rare events. Also, it is worth noting that co-cultures would have had large number of cells studied, as was the case in this study.

The low level of HIV-specific T cell responses, the low and declining levels of HIV-specific Ab in detuned and limiting antigen avidity assays, and the partial seroreversion [based on an indeterminate western blot] are all different from the usual course in antiretroviral-treated adults and “elite” controllers, suggesting very low to absent levels of HIV antigen. Indeed, the levels of residual HIV-specific Ab and T cells detected in this patient were considerably lower than those seen in chronically-infected individuals who have been on suppressive ART for many years, although low or undetectable HIV-specific immune responses have been observed in some patients treated early in the course of HIV infection [37,38,39]. Complicating this interpretation is the likelihood that the transplant procedure caused the loss or irreversible impairment of host B and T cells. In HIV-uninfected individuals who have undergone allogeneic stem cell transplant, serum antibodies to tetanus decay at variable rates, but remain detectable in half of patients for a year or more [40]. On the other hand, antibody levels to other infectious diseases, including some associated with latent viral infection, were present at typical levels and stable in the Berlin Patient over a 9 month period post-transplant. Based on these findings we propose that measurement of HIV-specific immune responses may prove to be a sensitive and accurate means to diagnosis an effective cure.

Given the multiple negative signals and the waning HIV-specific immunologic responses, it is possible that all of the positive signals were false positives. True verification of HIV persistence requires sequence confirmation. Unfortunately, the same factors that limit the ability to detect rare, low-level foci of HIV also make it difficult to amplify or clone rare sequences. No sequences are available from the sites where HIV was detected in the quantitative assays (plasma and gut), while the one available sequence comes from the PBMC, where HIV could not be detected in the quantitative assays, and differs from the pre-transplant consensus sequence. Although this sequence does not match any published sequence, it is possible that it is a contaminant from another clinical isolate. Opportunities for contamination may be higher during the nested PCRs and multiple steps used for env cloning than they may be in a one step, closed reaction for a quantitative real time PCR.

If one or more PCR signals is a true positive, one must ask why the HIV was not detected previously, and why is it now detected intermittently. It is possible that HIV persists at extremely low levels, perhaps in rare foci that are frequently missed in sampling. Another possibility is superinfection, especially since the PBMC sequence is predicted to be X4 tropic. Arguing against this possibility is that the vast majority of transmission occurs by one or a limited number of CCR5-utilizing virions [41,42]. HIV infection is extremely rare in homozygous CCR5Δ32 individuals [43,44,45,46,47,48,49], and transmission of X4 virus would be expected to result in sustained replication, which has not occurred.

If HIV persists, one must also question why it has failed to spread, and where it persists. The HIV could be R5-tropic, replication-defective, or unable to overcome his immune defenses. Anatomic sources could include the gut, brain, male genital tract, or lymphoid tissues such as the mesenteric lymph nodes and spleen. Cellular sources could include rare host hematopoietic cells, donor immune cells infected in a non-R5 dependent fashion [50,51], nonhematopoietic cells [such as neural progenitor cells, astrocytes, neurons, and oligodendrocytes 6], or cell-associated extracellular virus on the follicular dendritic network [13,14,52,53,54].

In addition to well-validated PCR, TMA, and in situ hybridization assays, we used whole transcriptome sequencing to search for HIV mRNA in the patient samples. Deep sequencing offers several advantages in HIV eradication studies. Because mRNA libraries incorporate all transcripts from each sample, the method’s sensitivity is not limited by differences between the sequences of synthetic primers or probes and a patient’s autologous viral sequences. In addition, all viral transcripts are quantified simultaneously, allowing characterization of differences in viral gene expression between different cell types, tissues, or individuals. Finally, concurrent sequencing of cellular transcripts allows
discernment of host factors, such as CCR5 genotype. It is important to acknowledge that the whole transcriptome sequencing performed here would be expected to detect cell-associated HIV RNA down to a level approximately two orders of magnitude lower than in viroptic patients. Therefore, the resulting data do not by themselves rule out a very low frequency of residual HIV RNA expressing cells in the patient. In future eradication studies, however, greater levels of sensitivity may be achieved by sequencing greater proportions of the mRNA libraries produced. Advances in library preparation and increases in data yield per unit cost may soon make this depth of sequencing routine, allowing detection of single HIV-infected cells within very large cell and tissue samples.

Despite the possibility of intermittently detectable, very low levels of HIV, the Berlin Patient has remained off of ART for 5 years, has no detectable viremia using standard assays, has waning HIV antibody levels, has limited to undetectable HIV-specific T cell responses, and has no evidence of HIV-related immunologic progression. The patient certainly meets any clinical definition for having achieved a long-term remission, and may even have had a sterilizing cure. Even the most extraordinary “elite” controllers described in the literature have more robust evidence for persistent infection [55]. Given that all assays are susceptible to false positive results, and given our inability to provide sequence confirmation, we cannot robustly document HIV persistence and hence conclude he has been cured. This inability to prove a negative is not unexpected, and will likely prove to be problem in future studies on curative interventions. Similar problems are emerging with regard to detection of persistence in other settings, including post-allogeneic stem cell transplants and potentially cured infants.

A key priority for the field is the development of robust, well-validated assays that can readily detect very low levels of virus. Future studies of eradication will ultimately require interruption of treatment and subsequent long-term observation as the gold standard for defining a successful outcome.

Acknowledgments

We thank Steven Lada (UCSD) and Steffney Rought (UCSD) for technical assistance. We also acknowledge Rebecca Hoh, Lorrie Epling, Ma Somsouk, Hiroyu Hatano, Jeffrey Martin, Rick Hecht, Vivek Jain, Richard Price and Peter Hunt for assistance in managing the clinical procedures. Finally, we would like to acknowledge the study participant, who made many sacrifices for this study, and who is very committed to advancing HIV cure research.

Author Contributions

Conceived and designed the experiments: S.A. Yukl, E. Boritz, M. Busch, C. Benten, T. Chun, D. Douek, A. Haase, Y. Ho, S. Keating, S. Palmer, C. Flècher, S. Pillai, M. Rothenberger, T. Schacker, J. Siliciano, R. Sinclair, M. Strain, J. Wong, D. Richman, S.G. Deeks. Performed the experiments: S.A. Yukl, E. Boritz, C. Benten, T. Chun, E. Eisele, Y. Ho, T. Lee, J.S. Justement, S. Keating, P. Li, D. Murray, S. Palmer, S. Pillai, R.W. Price, M. Rothenberger, J. Siliciano, E. Sinclair, M. Strain. Analyzed the data: S.A. Yukl, E. Boritz, M. Busch, C. Benten, T. Chun, D. Douek, E. Eisele, A. Haase, Y. Ho, G. Hutter, T. Lee, J.S. Justement, S. Keating, P. Li, D. Murray, S. Palmer, C. Flècher, S. Pillai, R.W. Price, M. Rothenberger, T. Schacker, J. Siliciano, R. Sinclair, E. Sinclair, M. Strain, J. Wong, D. Richman, S.G. Deeks. Contributed reagents/materials/analysis tools: C. Benten, G. Hutter, C. Flècher. Wrote the paper: S.A. Yukl, E. Boritz, M. Busch, T. Chun, D. Douek, R. Sinclair, M. Strain, D. Richman, S.G. Deeks.

References

1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 325: 1304–1307.
2. Deeks SG, Autran B, Berkhour B, Benkirane M, Cairns S, et al. (2012) Towards an HIV cure: a global scientific strategy. Nature reviews Immunology 12: 607–614.
3. Hutter G, Nowak D, Moots M, Gamepola S, Mussion A, et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. The New England journal of medicine 360: 692-698.
4. Allers K, Hutter G, Hofmann J, Lederkremer C, Rieger K, et al. (2011) Evidence for the cure of HIV infection by CCR5 Delta32/Delta32 stem cell transplantation. Blood 117: 2791–2799.
5. Symons J, Deeks S, Hutter G, Wensing A, Martin J, et al. (2012) The cure of the ‘Berlin patient’: why did pre-existing X4-variants not emerge after allogeneic CCR5-A32 SCT?. 19th International AIDS Conference. Washington, D.C.
6. Alexaki A, Liu Y, Wigdahl B (2008) Cellular reservoirs of HIV-1 and their role in viral persistence. Current HIV research 6: 388–400.
7. Palmer S, Maddrell F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America 105: 3879–3884.
8. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183–188.
9. Finzi D, Hermankova M, Pierson T, Carruth L, Buck C, et al. (1997) Identification of a reservoir for HIV in patients on highly active antiretroviral therapy. Science 278: 1295–1300.
10. Wong JK, Hezareh M, Gunhaard HF, Hadley DV, Ignacio CC, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291–1295.
11. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, et al. (1999) Persistent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine 5: 512–517.
12. Siliciano JD, Kajala J, Finzi D, Quinn TC, Chadwick K, et al. (2005) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727–728.
13. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, et al. (1996) Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274: 965–969.
14. Wong JK, Ganthard HF, Hadley DV, Zhang QZ, Haase AT, et al. (1997) Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A 94: 12574–12579.
15. Kuster H, Opriavil M, Ott P, Schlaper E, Fischer M, et al. (2000) Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infection. Am J Pathol 156: 1973–1986.
16. Bolli MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, et al. (2006) Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 45: 65–68.
17. Chun TW, Nettie DC, Justement JS, Meyers JH, Roby G, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. The Journal of infectious diseases 197: 714–720.
18. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202: 1553–1561.
19. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, et al. (2011) Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. The Journal of infectious diseases 204: 153–158.
20. Palmer S, Wiegand AP, Maddrell F, Baumi H, Mican J, et al. (2005) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41: 4531–4536.
21. Busch MP, Glynn SA, Wright DJ, Hirschhorn D, Laycock ME, et al. (2005) Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 45: 1833–1843.
22. Hatano H, Dubert E, Norris PJ, Lee TH, Dunn-Williams J, et al. (2009) Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol 83: 329–333.
23. Yukl SA, Li P, Fujimoto K, Lampiris H, Lu CM, et al. (2011) Modification of the Abbott RealTime assay for detection of HIV-1 RNA plasma viral loads less than one copy per milliliter. Journal of virological methods 175: 261–265.
24. Yukl SA, Harvill K, Gilman I, Ho H, Hunt PV, et al. (2012) Comparison of GALHT HIV RNA and DNA Levels in HIV-infected controllers, non-controllers, and HAART-suppressed individuals; 2012 March 5-8; Seattle, Washington.
25. Durand CM, Ghiaur G, Siliciano JD, Rabi SA, Eisele EF, et al. (2012) HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not...
found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. The Journal of infectious diseases 205: 1014–1018.

26. Strain MC, Lada SF, Luong T, Rought SE, Gianella S, et al. (2013) Highly Precise Measurement of HIV DNA by Droplet Digital PCR. PLoS one 8: e59546.

27. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JM, et al. (1997) Presence of an inducible HIV latent reservoir during highly active antiretroviral therapy. PNAS 94: 13193–13197.

28. Siliciano JD, Siliciano RF (2005) Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods in molecular biology 304: 5–13.

29. Keating SM, Hanson D, Lebedeva M, Lacvenderdecker O, Ali-Napo NL, et al. (2012) Lower-sensitivity and avidity modifications of the vireos anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation. Journal of clinical microbiology 50: 3968–3976.

30. Duong YT, Qui M, De AK, Jackson K, Dobbs T, et al. (2012) Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS ONE 7: e33329.

31. Ndhlovu LC, Sinclair E, Epling L, Tan QX, Ho T, et al. (2010) IL-2+CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. The Journal of Clinical Investigation 120: 173–184.

32. Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, et al. (2008) Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5: 107.

33. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, et al. (1991) Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes. J Virol 65: 3973–3983.

34. Sanchez G, Xu X, Chermann JC, Hirsch I (1997) Accumulation of defective viral genomes in peripheral blood mononuclear cells fo HIV infected individuals. Journal of Virology 71: 2233–2240.

35. Piatak M, Jr., Saag MS, Yang LC, Clark SJ, Kappes JC, et al. (1993) High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749–1754.

36. Eriksson S, Graf EH, Dahl V, Strain MC, Yuki SA, et al. (2013) Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradications Studies. PLoS pathogens 9: e1003174.

37. Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, et al. (2000) Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. Journal of virology 74: 6084–6091.

38. Binley JM, Tsiokas A, Ketas T, Schiller D, Clas B, et al. (2000) The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. The Journal of infectious diseases 182: 945–949.

39. Hare CB, Papparallo BL, Busch MP, Karlson AC, Phelps BH, et al. (2006) Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 42: 700–708.

40. Ljunngren P, Wiklund-Hammarsten M, Duraj V, Hammarstrom L, Lonnqvist R, et al. (1990) Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. The Journal of infectious diseases 162: 496–500.

41. Keele BF, Derdeyn CA (2009) Genetic and antigenic features of the transmitted virus. Current opinion in HIV and AIDS 4: 352–357.

42. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learm GH, Giorgi EE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. The Journal of experimental medicine 206: 1273–1289.

43. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856–1862.

44. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. (1996) Homozygous deletion in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367–377.

45. Samson M, Lihert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance to HIV-1 infection in caucassian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722–723.

46. Bin R, Ffrench R, Young J, Bennets B, Stewart G, et al. (1997) HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nature medicine 3: 252–253.

47. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C (1997) HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 349: 1219–1220.

48. O’Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, et al. (1997) HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 349: 1219.

49. Ballana E, Riveria-Munoz E, Pou C, Bach V, Parera M, et al. (2012) HLA class I protective alleles in an HIV-1-infected subject homozygous for CCR5-Delta32/Delta32. Immunobiology 218: 543–7.

50. Blanco J, Bosch B, Fernandez-Figueras MT, Barreina J, Cotlet B, et al. (2004) High level of coreceptor-independent HIV transfer induced by contacts between primary CD4+ T cells. The Journal of biological chemistry 279: 51305–51314.

51. Gorry PR, Dunlee RL, Medford ME, Kunstman K, Morgan T, et al. (2007) Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology 362: 163–176.

52. Schmitz J, van Lamzen J, Tenner-Racz K, Grosschupf G, Racz P, et al. (1994) Folicular dendritic cells retain HIV-1 particles on their plasma membrane, but are not productively infected in asymptomatic patients with follicular hyperplasia. Journal of immunology 153: 1352–1359.

53. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, et al. (2001) Persistence of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 287: 960–964.

54. Theodorou I, Meyer L, Magierowska M, Katlama C, Rouzioux C (1997) HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 349: 1219–1220.

55. Samson M, Lihert F, Doranz BJ, Rucker J, Liesnard C, et al. (1996) Resistance to HIV-1 infection in caucassian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722–723.

56. Kumar AM, Borodowsky I, Fernandez B, Gonzalez L, Kumar M (2007) Human immunodeficiency virus type 1 RNA Levels in different regions of human brain: quantification using real-time reverse transcriptase-polymerase chain reaction. J Neurovirol 13: 210–224.